Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions. - Wikidata - awgldk - TriplyDB

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

http://www.wikidata.org/entity/Q37157661

about

Inflammation in depression: is adiposity a cause?The association between chronic pain and obesity Systemic alterations in plasma proteins from women with chronic widespread pain compared to healthy controls: a proteomic study.Proinflammatory cytokine levels in fibromyalgia patients are independent of body mass index Potential Mediators between Fibromyalgia and C-Reactive protein: Results from a Large U.S. Community Survey.Relationship between fibromyalgia and obesity in pain, function, mood, and sleep.Cerebral responses to innocuous somatic pressure stimulation following aerobic exercise rehabilitation in chronic pain patients: a functional magnetic resonance imaging study Impact of fibromyalgia on functioning in obese patients undergoing comprehensive rehabilitation.Benefits of resistance exercise in lean women with fibromyalgia: involvement of IGF-1 and leptin Effect of milnacipran on body weight in patients with fibromyalgia Predictors of fibromyalgia: a population-based twin cohort study Clinical Manifestations Associated with Overweight/Obesity in Puerto Ricans with Fibromyalgia Syndrome.Exercise and obesity in fibromyalgia: beneficial roles of IGF-1 and resistin?Chronic Fatigue Syndrome and Chronic Widespread Pain in Adolescence: Population Birth Cohort Study.Fibromyalgia and obesity: the hidden link.Sleep disorders and fibromyalgia.Milnacipran for fibromyalgia: a useful addition to the treatment armamentarium.Fibromyalgia: A Critical and Comprehensive Review.Fibromyalgia: epidemiology and risk factors, a population-based case-control study in Lebanon.The association of total and central body fat with pain, fatigue and the impact of fibromyalgia in women; role of physical fitness.Ambroxol for the treatment of fibromyalgia: science or fiction?Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate.Clinical symptoms in fibromyalgia are associated to overweight and lipid profile.Depression in obese patients with primary fibromyalgia: the mediating role of poor sleep and eating disorder features.Effect of weight reduction on the quality of life in obese patients with fibromyalgia syndrome: a randomized controlled trial.Relationship of weight status with mental and physical health in female fibromyalgia patients.Serum levels of leptin and adiponectin and clinical parameters in women with fibromyalgia and overweight/obesity.Insulin resistance possible risk factor for cognitive impairment in fibromialgic patients.Obesity and sleepiness in women with fibromyalgia.Are there differences in quality of life, symptomatology and functional capacity among different obesity classes in women with fibromyalgia? The al-Ándalus project.Dietary aspects in fibromyalgia patients: results of a survey on food awareness, allergies, and nutritional supplementation.Association of body mass index with symptom severity and quality of life in patients with fibromyalgia.High fat diet sensitizes fibromyalgia-like pain behaviors in mice via tumor necrosis factor alpha.Relationships between body mass index, fat mass, muscle mass, and musculoskeletal pain in community residents.Controlled, cross-sectional, multi-center study of physical capacity and associated factors in women with fibromyalgia.Executive function impairments in fibromyalgia syndrome: Relevance of clinical variables and body mass index.The relationship between body mass index and pain, disease activity, depression and anxiety in women with fibromyalgia.

P2860

Q24635451-5814F920-720E-4668-AC29-481CFF70952A Q26800261-7270457E-8868-4B5E-8DC1-4F45998F647A Q33553977-88EB4C4F-C2A4-4CD4-95FC-1443CD89A55F Q33595115-B4CFE37D-07C6-42CB-A35B-D7F5F061BCE1 Q33882623-44B1F2C6-703A-412D-9BE0-4CFF1249B30B Q34129961-0B8B8054-CA7C-442B-89B6-CBCB7BE6E068 Q34134834-E1643DC7-A667-417A-A379-4DFF1F222E9D Q35117805-48C8CA85-0B1E-4639-AAB7-9DA05AB697EA Q36306712-3024F8A6-385C-48B6-8A02-EBDA74716D43 Q36344060-82F1029B-AA7D-42F5-9245-267D14393F8D Q36468997-8FBBE7D5-5EC3-40DF-88EC-1076BA7204B3 Q36538889-09B366F6-0258-4BA4-8D30-34ACCD906DD0 Q36903348-CFE9EA82-7D62-4D85-8E0B-582811807328 Q37685133-E7DD820D-3576-4404-B035-F415AB8E1573 Q37863057-A38B9304-20C4-435E-9632-BEC7045CF4E8 Q37877193-430AA1F9-8555-4308-BAD6-AD4D5A015DC7 Q38090730-B559F802-6377-4BC5-9A0D-82A33FCA06E8 Q38601633-A52D6C89-1772-4CD9-8EA3-6E72785EE549 Q40740111-379F6A3A-3DAD-4F77-B716-3D0A5A58D9E2 Q41193910-26543611-626B-4C99-B551-DB3FB3EA334F Q41483222-614AFC8F-6392-4206-9CE6-D7B1AE21BB16 Q43988174-BCA23F0E-BA4C-43D3-BEA6-2C2198EFFBF2 Q44961170-1E123658-A23A-4311-A158-4F7198AB25CB Q46176574-8C6CF3C1-7B33-4FF0-ABC1-656F697399C0 Q46657565-DC19211F-088B-4D02-8439-789BFB36AAED Q47331953-A323878C-52E7-4014-9E49-B75C74B2A09E Q47573772-76CD0B9E-6843-441A-A89D-BD05B24F9A76 Q47918459-4CA23B73-8143-4189-9ACA-F8ACA4D45CD5 Q48092195-BF37F554-F281-4C81-A04D-63084EA9A792 Q48119705-76D860A7-6099-407B-8AD8-346C2A04FD3B Q48288903-76F4BAB3-FA04-40D1-A2DD-BF625AC09627 Q48576972-46479D72-AAC7-4803-A747-F34FC2446A29 Q50000860-4AA86EA9-3862-4844-886F-374B46027D02 Q51115906-C27A3C30-FF64-4439-B92E-5C71B4293870 Q55112660-CCCAF321-7AFF-4619-BDEE-F88EC8A6A8BE Q55252507-DB11A4F3-E145-4155-B332-314364A9A2D2 Q55284663-48F7ACB1-A063-4BAA-A6A4-4BEB7BB82729

P2860

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

http://www.wikidata.org/entity/Q37157661

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 27 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

@en

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

@nl

type

label

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

@en

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

@nl

prefLabel

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

@en

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

@nl

P1433

Q37157661-BC6C2462-19DA-4AD5-BBFC-95FCD2F2FDB1

P1476

Q37157661-78FE4446-E8C4-4B0D-B0A9-F81B7C522DFD

P2093

Q37157661-D6B48DF1-7801-4B24-80E3-BE6BA9C04A72

Q37157661-ECCC86BA-F212-47D0-99FB-79CD974271FC

Q37157661-F99ED865-754E-4511-A375-C961A3D5AC8D

P2860

Q37157661-2744D273-19D1-494D-8F36-8780CEF970A3

Q37157661-2A9DFDD8-4A1C-466D-81C0-9303A78E8EF6

Q37157661-4FAFFF1B-CFE5-4597-A4D9-8F50BDA6C77C

Q37157661-509E6A27-BE55-49EC-AB59-47747BB7E066

Q37157661-62E67826-8F96-4B93-8A91-7884F8DA9C84

Q37157661-7C69EFED-A665-4317-8F4C-9EF1B0B0DCA1

Q37157661-874A71A1-3484-422C-8F05-CAAF1EF73BB6

Q37157661-C02180DF-DD9A-42AC-908B-E2D1E6A6D169

Q37157661-E728BDB5-FF7E-47B2-A2AE-383107926467

Q37157661-F1DDFD18-86BB-44CF-AE2E-A90CE2B5BB68

P304

Q37157661-815A7E95-7FCA-4FA5-9D06-795BEC678139

P31

Q37157661-5D71BF07-14DC-4F26-BF4A-E9905537BF7B

P356

Q37157661-83F29A99-AFB6-4C07-8F09-8886631BE7B2

P433

Q37157661-5D8E9640-49A7-46B1-B602-C1EF37C805FA

P478

Q37157661-2F13D91A-2612-41E9-8719-7786A364F642

P577

Q37157661-707EAEC2-5DD6-4347-A7BE-847C4054158B

P5875

Q37157661-772DCB87-7436-48BA-80ED-2D2059F7A696

P698

Q37157661-7942A37A-E658-46B4-9B50-1994479D9356

P921

Q37157661-A029898A-11EF-4B62-AA85-1A23CCA09E83

Q37157661-C5C2F951-BDA5-4788-B1D7-D1FF6A8A42D5

Q37157661-E799DE6D-CAF3-47ED-B4A0-CC624986735B

Q37157661-F5DEB9A3-0062-4877-9D1B-945EC532B5C4

P932

Q37157661-DF1A8102-0F16-4EB2-8D48-A113370F49B9

P356

S10067-009-1094-2

P1433

Clinical Rheumatology

P1476

Evaluating obesity in fibromyalgia: neuroendocrine biomarkers, symptoms, and functions.

@en

P2093

Akiko Okifuji

http://www.w3.org/2001/XMLSchema#string

Chrisana Olson

http://www.w3.org/2001/XMLSchema#string

David H Bradshaw

http://www.w3.org/2001/XMLSchema#string

P2860

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

The obesity pandemic: where have we been and where are we going?

Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002.

Central sensitization in fibromyalgia and other musculoskeletal disorders.

The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses.

Is there a role for cytokine based therapies in fibromyalgia.

The significance, assessment, and management of nonrestorative sleep in fibromyalgia syndrome.

Exercise for fibromyalgia: a systematic review.

Obesity and migraine: a population study.

Association of interleukin-6, C-reactive protein, interleukin-10 and adiponectin plasma concentrations with measures of obesity, insulin sensitivity and glucose metabolism.

P304

475-478

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10067-009-1094-2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23951481

http://www.w3.org/2001/XMLSchema#string

P698

19172342

http://www.w3.org/2001/XMLSchema#string

P921

neuroendocrinology

P932

2668698

http://www.w3.org/2001/XMLSchema#string